Nontraditional Risk Factors For Heart Disease Require More Study
This article was originally published in The Gray Sheet
More evidence is needed to determine whether screening for nine nontraditional risk factors would help better define patients' risk of coronary heart disease, according to an Oct. 6 assessment by the U.S. Preventive Services Task Force
You may also be interested in...
Experts are not ready to call for an expansion of high-sensitivity C-reactive protein (hsCRP) testing, even though new trial results show elevated CRP testing can identify patients with low cholesterol who might benefit from statin drugs
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.